Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest announcement is out from Cidara Therapeutics ( (CDTX) ).
On June 23, 2025, Cidara Therapeutics announced positive results from its Phase 2b NAVIGATE trial for CD388, a drug aimed at preventing seasonal influenza. The trial demonstrated statistically significant prevention efficacy across all dose groups, with CD388 being well-tolerated and showing no unexpected adverse events. These results could enhance Cidara’s positioning in the antiviral market, and the company has submitted a meeting request to the FDA to discuss the Phase 3 trial design.
The most recent analyst rating on (CDTX) stock is a Buy with a $45.00 price target. To see the full list of analyst forecasts on Cidara Therapeutics stock, see the CDTX Stock Forecast page.
Spark’s Take on CDTX Stock
According to Spark, TipRanks’ AI Analyst, CDTX is a Neutral.
Cidara Therapeutics is in a challenging position financially, with significant revenue declines and negative cash flows weighing heavily on its prospects. While technical indicators and valuation metrics paint a grim picture, the potential of CD388 and strategic corporate actions offer some hope for future recovery. Nevertheless, the current financial and operational challenges are substantial, resulting in a low overall stock score.
To see Spark’s full report on CDTX stock, click here.
More about Cidara Therapeutics
Cidara Therapeutics, Inc. operates in the biotechnology industry, focusing on the development of long-acting therapeutics designed to improve the standard of care for patients facing serious diseases. The company is particularly known for its work on antiviral and antifungal drugs, including its novel Drug-Fc-Conjugate (DFC) platform.
Average Trading Volume: 171,175
Technical Sentiment Signal: Hold
Current Market Cap: $272.6M
For a thorough assessment of CDTX stock, go to TipRanks’ Stock Analysis page.